BioTech IQ
95 episodes - English - Latest episode: 11 months ago - ★★★★★ - 9 ratingsIncrease your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science, clinical operations, clinical development, safety/PV and more! We address how each function plays an important role in the drug approval process. We also discuss the people that make up these departments. Get ready to hear about cutting edge development and the people who make it happen!
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
#66 Seasoned Biotech Executive talks T-Cell Therapy and Running a Business in 2023!
May 26, 2023 14:00 - 52 minutes - 36.2 MBOn this episode of BioTech IQ, Ammon interviews Paul Lammers the CEO of Triumvira about developing autologus cell therapies using their T-Cell Antigen Coupler Platform (TAC). During this insightful discussion Paul talks about how he started in the industry, running a biotech company in today's environment, and what sets Triumvira's T-Cell therapy apart from the rest! Don't miss it! Show support for show https://www.buymeacoffee.com/biotechiq Check out the books recommended by Paul: CEO Exc...
#65. A Journey From Investment Banker To The CEO Of A Biotech Developing Cancer Therapy With Bryan Kobel
April 07, 2023 11:00 - 50 minutes - 34.5 MBBryan Kobel decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of TC BioPharm, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which i...
#64 A Professional Recruiters Perspective on The State of Hiring in Biotech!
March 17, 2023 17:00 - 29 minutes - 20.3 MBIn this episode of BioTech IQ Ammon shares some real stats on the state of the hiring market in Biotech/pharma. We discuss what both job seekers and hiring managers can do to increase their success when searching/hiring. Bringing innovative treatments that make a difference in the life of people is the goal but the business side of drug development is as complex as the science sometimes. Don't miss it! Leave a review and share! Thanks! Support the show here: https://www.buymeacoffee.com/bi...
#63 From writing a newspaper column at age 7 to becoming a BioTech CEO: Cary Claiborne Sr.
February 25, 2023 16:00 - 49 minutes - 33.7 MBCary Claiborne Sr. is the CEO of Adial Pharmaceuticals and member of the board. He also sits on the board for Nuerosense Therapeutics and CytRx. Cary holds an MBA from Villanova University. In this episode Cary shares how his interest in finance at an early age led him to become the CFO of a small biotech that led him to where he is today. Support the show: https://www.buymeacoffee.com/biotechiq Books that Cary referenced: Holy Bible - https://amzn.to/3Y6um4W Control Your Destiny or Someon...
#62 Biotech Consultant Shares Her Thoughts on Where We are Headed: It's About Innovation!
January 20, 2023 14:00 - 59 minutes - 40.8 MBOn this episode of BioTech IQ Ammon interviews Farahnaz Forozan, PhD, MB who is a 20 year veteran in the industry. She discussed how she immigrated from Iran to the United States, became a Phd, was the Head of Translational Development with BMS, to running her own consulting practice. She has taken all this experience and is driving innovation within biotech. Don't miss it! It's about Innovation. www.forozanoncogenconsulting.com Support the show here: https://www.buymeacoffee.com/biotechi...
#61 Tunable Radio Pharmaceuticals? The Founders of Ratio Therapeutics.
January 07, 2023 01:00 - 58 minutes - 40 MBThroughout many of the discussions on BioTech IQ it is clear that a combination of therapies is likely the answer to treating cancers and other diseases. This is a point well made by the guests on this episode of the show. CEO Jack Hoppin, PhD and Chief Scientific Officer, John Babich PhD are Co-Founders of Ratio Therapeutics. Both bring a successful background in biotech and not only discuss what their organization is doing but lessons they have learned as entrepreneurs in treatment develop...
Biotech Chief People Officer Discusses How To Build Company Culture
December 18, 2022 00:00 - 38 minutes - 26.8 MBScience will only get you so far in biotech. No matter how ingenious your products are, you will never succeed as a company if you don’t have all the pieces if business development in place. And there is no greater piece than the people piece. As the Chief People Officer of Biomea Fusion, Naomi Cretcher knows that company culture is what is going to make or break her company’s success. Despite everything that went on with COVID and with a recession looming, Naomi is confident that investing ...
#60 Biotech Chief People Officer Discusses How To Build Company Culture
December 18, 2022 00:00 - 38 minutes - 26.8 MBScience will only get you so far in biotech. No matter how ingenious your products are, you will never succeed as a company if you don’t have all the pieces if business development in place. And there is no greater piece than the people piece. As the Chief People Officer of Biomea Fusion, Naomi Cretcher knows that company culture is what is going to make or break her company’s success. Despite everything that went on with COVID and with a recession looming, Naomi is confident that investing ...
BioTech IQ Update
December 10, 2022 17:00 - 17 minutes - 12.2 MBAmmon shares an update what has changed and why no new episodes have been release for the last couple of months. And discussing some interesting facts about the biotech industry and where it's headed from a hiring perspective. Atlas 2022 Year in Review https://youtu.be/LONM9ekseJ4 Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
#59 M2GEN's Platform For More Accurate and Faster Oncology Clinical Trial Recruitment
November 01, 2022 22:00 - 41 minutes - 28.2 MBIn this epsisode of BioTech IQ Ammon interviews the Chief Growth Officer of M2GEN Todd Johnson, MD. M2GEN partners with 18 of the nation’s leading cancer centers, through the Oncology Research Information Exchange Network® (ORIEN), to deliver oncology informatics-based solutions to accelerate therapy discovery, development and delivery of precision medicine. M2GEN is one of the only companies to ensure that patient data has been granted through consent. M2GEN utilizes the IRB-approved proto...
#58 Qualigen Therapeutics: How To Develop An Oncology Therapeutics Pipeline From A CMO's Perspective With Tariq Arshad, MD
October 21, 2022 23:00 - 44 minutes - 30.9 MBThere isn’t a cure for cancer yet, but if everyone can come together, we may find that cure sooner rather than later. One biotech company that is trying to solve cancer is Qualigen Therapeutics. With their oncology therapeutics pipeline, they could be onto something with their leading asset QN-302. Join Ammon Rivera as he talks to the Chief Medical Officer of Qualigen Therapeutics, Tariq Arshad, MD, about where they are right now in their therapeutics pipeline. Learn why cancer is the grea...
Qualigen Therapeutics: Where It All Started And Where It's Going With Founder And CEO Michael Poirier
October 07, 2022 11:00 - 41 minutes - 28.7 MBIn this episode of BioTech IQ, Ammon Rivera continues his exploration of Qualigen Therapeutics by interviewing the founder and CEO of the company Michael Porier. Michael discusses how Qualigen was started and the motivation behind the therapeutics pipeline. There are incredible developments underway for the company, and the turn of the market is hopefully on its way as well. Listen in on their discussion about the growth of Qualigen and what investors can look forward to as they continually ...
#56 Qualigen Therapeutics: How Do You Develop A Successful Therapeutics Pipeline In Oncology With Amy Broidrick
September 16, 2022 14:00 - 46 minutes - 32.1 MBQualigen Therapeutics is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the last few years. In this first episode of a three-part series featuring top executives of Qualigen Therapeutics, Ammon interviews Amy Broidrick, the firm's President and Chief Strategy Officer. She shares what she brings to the table in the company's trans...
#56 Qualigen Therapeutics: How Do You Develop A Successful Therapeutics Pipeline In Oncology With Amy Broidrick
September 16, 2022 14:00 - 46 minutes - 32.1 MBQualigen Therapeutics is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the last few years. In this first episode of a three-part series featuring top executives of Qualigen Therapeutics, Ammon interviews Amy Broidrick, the firm's President and Chief Strategy Officer. She shares what she brings to the table in the company's trans...
Mapping The Human Immune System: Using AI To Change Drug Development With Noam Solomon
September 05, 2022 23:00 - 48 minutes - 33.2 MBAI has gone so far as to potentially change drug development, and these developments have the potential to make a difference in people’s lives. On this episode of BioTech IQ, Ammon interviews Noam Solomon, the CEO of Immunai. Immunai is developing an AI platform that leverages big data, single cell multiomics, and machine learning to bridge the gap between casual immunology and translational disease biology. Their platform is mapping the human immune system at an unprecedented level of granu...
#55 Mapping The Human Immune System: Using AI To Change Drug Development With Noam Solomon
September 05, 2022 23:00 - 48 minutes - 33.2 MBAI has gone so far as to potentially change drug development, and these developments have the potential to make a difference in people’s lives. On this episode of BioTech IQ, Ammon interviews Noam Solomon, the CEO of Immunai. Immunai is developing an AI platform that leverages big data, single cell multiomics, and machine learning to bridge the gap between casual immunology and translational disease biology. Their platform is mapping the human immune system at an unprecedented level of granu...
#54 Going Beyond The Current Standard Of Care For Anxiety, Depression, And CNS Disorders With Shawn Singh
July 23, 2022 23:00 - 46 minutes - 31.8 MBSocial anxiety disorder is the third most common mental health disorder. Over 23 million Americans alone are affected by it. This disorder can continue to grow into depression and drug abuse, so it's very important to catch it early so it can be stopped. But how can it be stopped? Shawn Singh, the CEO and Director of VistaGen Therapeutics, and his team are creating a nasal spray to help people with social anxiety disorder. Just like an inhaler for asthma, this nasal spray can do for soci...
#53 Going Beyond The Current Standard Of Care For Anxiety, Depression, And CNS Disorders With Shawn Singh
July 23, 2022 23:00 - 46 minutes - 31.8 MBSocial anxiety disorder is the third most common mental health disorder. Over 23 million Americans alone are affected by it. This disorder can continue to grow into depression and drug abuse, so it's very important to catch it early so it can be stopped. But how can it be stopped? Shawn Singh, the CEO and Director of VistaGen Therapeutics, and his team are creating a nasal spray to help people with social anxiety disorder. Just like an inhaler for asthma, this nasal spray can do for soci...
#52 Harnessing the Innate Immune System By Developing Three Types of iPSC-Derived Natural Killer Cells With Daniel Teper
July 15, 2022 23:00 - 32 minutes - 22.1 MBCompanies in the biotech space are making contributions to help find a cure for cancer. Today’s guest is no exception. In today’s episode, Ammon Rivera sits down with Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology they’re using to develop a treatment for cancer. Daniel discusses how they’ve developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of di...
#53 Harnessing the Innate Immune System By Developing Three Types of iPSC-Derived Natural Killer Cells With Daniel Teper
July 15, 2022 23:00 - 32 minutes - 22.1 MBCompanies in the biotech space are making contributions to help find a cure for cancer. Today’s guest is no exception. In today’s episode, Ammon Rivera sits down with Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology they’re using to develop a treatment for cancer. Daniel discusses how they’ve developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of di...
#52 How is Anima Biotech changing the game on identifying the mechanism of action?
July 01, 2022 21:00 - 1 hour - 42.5 MBOn this episode of BioTech IQ Ammon talks with Co-Founder and CEO of Anima Biotech, Yochi Slonim. Yochi is a serial entrepreneur with experience building multiple successful companies before starting Co-Founding Anima. Anima Biotech is developing mRNA Lighting, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action. Automated high scale phenotypic screening combining live biology with AI mRNA image analysis for the discovery of small molecule...
#51 Cell Cycle Therapy: Understanding The Cell Cycle Biology To Treat Cancer With Spiro Rombotis
June 10, 2022 23:00 - 55 minutes - 38.2 MBCell cycle biology is key to understanding cancer. You have to hit the cancer cells early before they become smart and adapt. There is a stage in the cell cycle called mitosis. This is where, if done right, can cause cancer cells to suicide. This is where the biotech company, Cyclacel comes in with all their research into the cell cycle of cancer. Join Ammon Rivera as he talks to Spiro Rombotis about some of Cyclacel's cell cycle therapies. Spiro is the CEO of Cyclacel. His mission is to use...
#50 Can Lineage Cell Therapeutics Proprietary Cell-Based Therapy Platform Change Treatment Development?
May 27, 2022 23:00 - 38 minutes - 26.8 MBHave you ever thought about having replacement parts for your body? It sounds like science fiction, but it’s now as real as the eyes you’re using to read this, thanks to cell-based therapy. Brian Culley is one of the leaders in this field. He is the CEO of Lineage Cell Therapeutics, a company developing treatments for multiple indications based on their proprietary cell-based therapy platform. Leveraging in-house manufacturing, they are attacking multiple indications from ophthalmology to im...
#49 Global Tensions And Supply Chains And Their Effect On Biotech. Guillermo Morales, PhD, CEO Of Innoventyx
May 17, 2022 23:00 - 53 minutes - 36.9 MBThe biotech industry has been bombarded with disruptions in recent years, from a global pandemic to rising global tensions. How are they dealing with the supply chain issues and how else has it impacted the industry? In this episode, Ammon Rivera sits down with two-peat guest, Guillermo Morales, PhD, CEO of Innoventyx. Guillermo makes us privy to the issues brought on by COVID-19 and the geopolitical tensions such as the Russia-Ukraine conflict. He also discusses intellectual property in gre...
#48 Market Discussion and Real Life Recruiting Experiences
May 13, 2022 17:00 - 24 minutes - 17.2 MBIn this episode of BioTech IQ host Ammon Rivera talks about the current state of the market with respect to recruiting. He also shares a real and recent experience highlighting the challenges of compensation and it role in landing the right individual for the job. https://thebiotechiqpodcast.com/ https://www.linkedin.com/in/ammonr/ Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
#47 Can Hepion Pharmaceuticals Develop the First Treatment Approved For NASH? With Robert Foster, Pharm D, PhD
April 29, 2022 18:00 - 52 minutes - 36.2 MBOn this episode of BioTech IQ, Ammon Rivera interviews Robert Foster Pharm D, PhD, CEO of Hepion Pharmaceuticals. Robert brings 30 years of experience to this discussion and shares with us details of his background that led him to where he is today. We also discuss Hepion Pharmacetuicals current clinical trials to development treatments targeting chronic liver diseases including NASH, cancer, and chronic hepatitis virus infection. A quarter of the people in the US have fatty livers and of th...
#46 How Is Translational Genomics Reducing Background Noise In Multi-Disease Detection? With Aiguo "Adam" Zhang
April 22, 2022 15:00 - 40 minutes - 27.9 MBSome of the main problems with sequencing in identifying mutations are its cost and the time it takes. Fortunately, with the rapid growth of technology, revolutionary products that simplify processes are being made. One of those is from DiaCarta, a diagnostics company using translational genomics and molecular precision technology to develop ways of detecting disease. In this episode of BioTech IQ, Ammon Rivera interviews its CEO, Adam Zhang. Their patented technology reduces the "background...
#45 Does company culture really affect drug development?
April 15, 2022 23:00 - 41 minutes - 28.2 MBIn this episode of BioTech IQ Ammon interviews professional coach Jeff Harmon. Jeff specializes in working with life science companies by helping them develop their unique company cultures that drives success at all levels. Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
#44 Addressing One Of The World’s Biggest Drivers Of Disease: Inflammation With Jim Woody, M.D., Ph.D. - CEO 180 Life Sciences
April 01, 2022 08:00 - 46 minutes - 31.9 MBTNF is a protein that contributes to inflammation. Anti-TNFs can be used to stabilize this and stop the inflammation. It's used for diseases like arthritis and psoriasis. Discover how clinical trials are done so these medicines and anti-TNFs can be utilized. Join Ammon Rivera as he talks to M.D., Ph.D. and CEO of 180 Life Sciences, Jim Woody about anti-TNFs and the trial process behind them. Jim's goal is to address one of the biggest drivers of disease – inflammation. Learn more about Jim's...
#43 How to leverage past experience in developing treatments for rare disease. James Mackay, PhD - CEO, Aristea Therapeutics
March 25, 2022 08:00 - 50 minutes - 34.5 MBThis episode of BioTech IQ features James Mackay, PhD, Founder and CEO of Aristea Therapeutics. Aristea Therapeutics is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. In particular, their lead asset is addressing palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States that affects about 100,000 people. Don't miss this episode as we discuss James' ...
#42 Regenerative Medicine? How two companies are attacking nerve damage.
March 12, 2022 00:00 - 1 hour - 45.8 MBThis episode on BioTech IQ is actually a recording of two separate interviews. In the first half of the show I interview Pete Mariani who is the CFO of Axogen, Inc. Pete has strong experience in public markets experience including successful raises of equity, debt and strategic financing; driving strong, consistent investor communication and strategies; and establishing solid SEC reporting structures. The second guest is Robert w. Mays, Ph.D, Co-Founder and Vice President of Regenerative M...
#41 Is axonal transport the key to solving neurodegenerative diseases? Maria Maccechini, PhD - CEO, Annovis Bio
March 04, 2022 22:00 - 48 minutes - 33.6 MBOn this episode of BioTech IQ Ammon interviews Maria Maccechini is an accomplished scientist, successful biotech executive, and angel investor. She is the CEO of Annovis Bio, Attacking Alzheimer's Disease and Neurodegeneration by Improving AXONAL TRANSPORT , this enhances the FLOW of Information Along the Information Highway of Nerve Cells. https://www.annovisbio.com/ https://thebiotechiqpodcast.com/ Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
#40 Treatments that can reach beyond on the function of drugs? James Joyce, CEO - Sigyn Therapeutics
February 25, 2022 21:00 - 33 minutes - 23 MBJames Joyce is the CEO, Chairman of the board, and a co-founder at Sigyn Therapeutics. Did you know that multiple healthcare agencies report "community acquired pneumonia" as the number cause of infectious disease death? And this indication leads to about 50% of sepsis cases? On this episode of BioTech IQ we discuss Sigyn Therapeutics blood purification device can calm the storm and change that. https://www.sigyntherapeutics.com/ https://thebiotechiqpodcast.com/ https://www.linkedin.com/in...
#39 How can digital health change the success of patient care? Waqaas Al-Siddiq, DBA, CEO - Biotricity
February 18, 2022 22:00 - 36 minutes - 24.9 MBDid you you know that 70% of costs related to patient care are spent on chronic conditions? In this episode of BioTech IQ we talk with Founder and CEO of Biotricty on how their technology is changing the landscape for patient care in the cardiovascular space. https://thebiotechiqpodcast.com/ https://www.linkedin.com/in/ammonr/ https://www.biotricity.com/ Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
Bonus Episode! Digital Health Panel with Biotricity and DarioHealth
February 17, 2022 18:00 - 56 minutes - 38.9 MBLive interview with Dr. Waqaas Al-Siddiq, DBA, CEO of Biotricity and Omar Manejwala, M.D. Chief Medical Officer at Dario Health. We have a discussion on what is digital health, the problems it's solving, and the major opportunity it is for patients, physicians, and investor alike. https://thebiotechiqpodcast.com/ https://youtu.be/ZQP2Nra7BgY https://www.biotricity.com/ https://www.dariohealth.com/ #digitalhealth #biotechiq #biotechiqlife Support the show Check me out on LinkedIn https://ww...
#37 How many lives would be changed with effective prevention of thromboembolic events? John Glasspool, CEO of Anthos Therapeutics
February 11, 2022 21:00 - 56 minutes - 38.8 MBAn interview with John Glasspool, CEO of Anthos Therapeutics. Did you know that VTE is the 2nd leading cause of death in cancer patients after the cancer itself? Did you know that many patients choose not to us the current standard of care to blood clotting due to excessive bleeding? Anthos Therapeutics is addressing this major unmet medical need in thromboembolic events with their lead candidate abelacimab. Abelacimab is an investigational monoclonal antibody that achieves profound suppress...
#36 Can Shoreline Biosciences change the future of cell therapy through pluripotent stem cells?
February 04, 2022 05:00 - 43 minutes - 30.1 MBThis episode of BioTech IQ features Kleanthis Xanthopoulos, Ph.D. He is the co-founder, chairman of the board, and CEO of Shoreline Biosciences. As part of our "What's Ahead in Biotech: #2022" series Kleanthis talks about the power of induced pluripotent stem cells (iPSC) derived NK cells, and macrophage immunotherapies. What is the future of immunotherapies? Listen and find out! https://shorelinebio.com/ https://thebiotechiqpodcast.com/ Support the show Check me out on LinkedIn https://...
#36 Can Shoreline Biosciences change the future of cell therapy through pluripotent stem cells?
February 04, 2022 05:00 - 43 minutes - 30.1 MBThis episode of BioTech IQ features Kleanthis Xanthopoulos, Ph.D. He is the co-founder, chairman of the board, and CEO of Shoreline Biosciences. As part of our "What's Ahead in Biotech: #2022" series Kleanthis talks about the power of induced pluripotent stem cells (iPSC) derived NK cells, and macrophage immunotherapies. What is the future of immunotherapies? Listen and find out! https://shorelinebio.com/ https://thebiotechiqpodcast.com/
#35 Can Biomea Change the World with Irreversible Drugs and Covalent Bonds? Thomas Butler, CEO - Biomea Fusion
January 04, 2022 20:00 - 1 hour - 44.5 MBTom shares with us some of his journey and how that led him to co-found Biomea Fusion. We discuss some of the science behind irreversible drugs and covalent bonding. Using their fusion system there is greater potential for high selectivity, deep inactivation of target, and a greater therapeutic window. https://biomeafusion.com/ https://thebiotechiqpodcast.com/podcast/ Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
#33 Reducing friction at Clinical Trial Start-Up - Sam Searcy, CEO of CliniStart
December 18, 2021 18:00 - 53 minutes - 37 MBCliniStart launched to provide innovative tech-enabled solutions focused on global investigator contracts, budgets, and payments. And they did all of this just as the COVID-19 pandemic was hitting. This gave them an opportunity to shift and adapt. In this episode we address the challenges causing friction at during clinical trial start-up and what it takes to launch a start-up company. https://clinistart.com/ Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
#32 People, the most valuable asset a business has. Brenda Sousa - Chief HR Officer
December 13, 2021 17:00 - 1 hour - 44.2 MBOn this episode we have Brenda Sousa, previously the Chief Human Resources Officer with Constellation Pharmaceuticals. Brenda shares with us part of her backstory and entry into the world of Biotech. We discuss people, culture, the function of HR, and how the industry requires a unique yet similar approach. Ammon also shares past experiences with Brenda and gets her take on them. #BiotechIQ #Biotech #Drugdevelopment #Recruiting #Staffing Support the show Check me out on LinkedIn https://www...
#31 Managing CRO relationships and unique business models - Stewart Hallet - COO SFJ Pharmaceuticals
November 24, 2021 18:00 - 1 hour - 44.2 MBIn this episode of BioTech IQ Ammon interviews Stewart Hallet the COO of SFJ Pharmaceuticals, a specialty pharmaceutical company with a unique business model. The discussion touches on a number of things in clinical operations including working with CROs, leadership, and resourcing. #BioTechIQ #ClinicalOperations #DrugDevelopment #Podcasts Support the show Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
#30 Brazen Bio Part II - Live and In Person!
November 04, 2021 06:00 - 40 minutes - 27.7 MBCo-founders Shawn Carbonell and Brent Witgen discuss the progress of the 1st cohort (BRZN1) as they are well into the Brazen Bio program. We also get the chance to interview one of the founders currently in the program. We discuss what he is working on and what his experience has been in the program. Do you have a project that needs acceleration? Then don't hesitate, go to brazen.bio and get your application in for the next cohort. Support the show Check me out on LinkedIn https://www.linked...
#29 Why do we resist? Applying clinical psychology to clinical trials. Kathleen Starr, PhD - EVP Behavioral Insights, Syneos Health
October 29, 2021 16:00 - 57 minutes - 39.7 MBKathleen shares fantastic insights on understanding behavioral psychology and how it applies to successful clinical trials. We had a great conversation that touched on increasing diversity in trials to understanding our own behavior and how we can potentially understand patients better. This can be applied in a way to close the gap between intention and action. Kathleen co-authored a Book called "Why We Resist: The Surprising Truths about Behavior Change: A Guidebook for Healthcare Communica...
#29 Why do we resist? Applying clinical psychology to clinical trials. Kathleen Starr, PhD - EVP Behavioral Insights, Syneos Health
October 29, 2021 16:00 - 57 minutes - 39.8 MBKathleen shares fantastic insights on understanding behavioral psychology and how it applies to successful clinical trials. We had a great conversation that touched on increasing diversity in trials to understanding our own behavior and how we can potentially understand patients better. This can be applied in a way to close the gap between intention and action. Kathleen co-authored a Book called "Why We Resist: The Surprising Truths about Behavior Change: A Guidebook for Healthcare Communica...
#28 Vaccine Durability, Diversified Pipeline, Winning Strategy - Seth Lederman, MD - CEO Tonix Pharmaceuticals
October 01, 2021 18:00 - 56 minutes - 38.8 MBSeth Lederman is the CEO of Tonix Pharmaceuticals and a physician scientist with a two decades of research experience. Prior to becoming an entrepreneur, he was an Associate Professor at Columbia University. Dr. Lederman’s groundbreaking research led to the discovery of the CD-40 ligand and its role in T cell helper function. Currently, Dr. Lederman oversees Tonix Pharmaceuticals and its diverse programs that are aimed to develop therapeutics for chronic CNS and immunologic conditions, that ...
Vaccine Durability, Diversified Pipeline, Winning Strategy - Seth Lederman, MD - CEO Tonix Pharmaceuticals
October 01, 2021 18:00 - 56 minutes - 38.7 MBSeth Lederman is the CEO of Tonix Pharmaceuticals and a physician scientist with a two decades of research experience. Prior to becoming an entrepreneur, he was an Associate Professor at Columbia University. Dr. Lederman’s groundbreaking research led to the discovery of the CD-40 ligand and its role in T cell helper function. Currently, Dr. Lederman oversees Tonix Pharmaceuticals and its diverse programs that are aimed to develop therapeutics for chronic CNS and immunologic conditions, that ...
#27 How do you effectively manage the CMC process? Doug Looker, PhD - VP Preclinical Development
September 21, 2021 01:00 - 29 minutes - 20.2 MBDoug Looker is the VP of Preclinical Development and Manufacturing with Amicrobe, Inc. A company engineering proteins to prevent and treat infections. Doug walks us the through the process of establishing the CMC process that will drive success at every stage of the clinical trial process. And we have a brief discussion on animals being used in trials. https://www.amicrobe.com/
#27 How do you effectively manage the CMC process? With Doug Looker, PhD
September 21, 2021 01:00 - 29 minutes - 20.2 MBDoug Looker is the VP of Operations with Validus Cellular Therapeutics. Validus is using cellular therapy to target infections by fighting the biology of antimicrobial resistance by activating the biology of the mammalian immune system. Doug walks us the through the process of establishing the CMC process that will drive success at every stage of the clinical trial process. And we have a brief discussion on animals being used in trials. During the recording and editing of this episode Doug ...
#27 How do you effectively manage the CMC process? Doug Looker, PhD - VP Pre-Clinical Development
September 21, 2021 01:00 - 29 minutes - 20.2 MBDoug Looker is the VP of Pre-Clinical Development and Manufacturing with Amicrobe, Inc a company engineering proteins to prevent and treat infections. Doug walks us the through the process of establishing the CMC process that will drive success at every stage of the clinical trial process. And we have a brief discussion on animals being used in trials. https://www.amicrobe.com/